RT Journal Article
SR Electronic
T1 Caspases in COVID-19 Disease and Sequela and the Therapeutic Potential of Caspase Inhibitors
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.02.20223636
DO 10.1101/2020.11.02.20223636
A1 Matthew Plassmeyer
A1 Oral Alpan
A1 Michael J. Corley
A1 Kimberleigh Lillard
A1 Paige Coatney
A1 Tina Vaziri
A1 Suzan Michalsky
A1 Thomas A. Premeaux
A1 Alina P.S. Pang
A1 Zaheer Bukhari
A1 Stephen T. Yueng
A1 Teresa H Evering
A1 Gail Naughton
A1 Martin Latterich
A1 Philip Mudd
A1 Alfred Spada
A1 Nicole Rindone
A1 Denise Loizou
A1 Lishomwa C. Ndhlovu
A1 Raavi Gupta
YR 2020
UL http://medrxiv.org/content/early/2020/11/04/2020.11.02.20223636.abstract
AB Currently, there is no effective vaccine and only one FDA approved early-stage therapy against SARS-CoV-2 infection as an indication to prevent disease progression. Cellular caspases play a role in the pathophysiology of a number of disorders that the co-morbid conditions seen in severe COVID-19 disease. In this study, we assessed transcriptional states of caspases in blood cells from COVID-19 patients. Gene expression levels of select caspases were increased in in vitro SARS-CoV-2 infection models and single cell RNA-Seq data of blood from COVID-19 patients showed a distinct caspase expression in T cells, neutrophils, and dendritic cells. Flow cytometric evaluation of CD4 T cells showed up-regulation of caspase-1 in hospitalized COVID-19 patients compared to unexposed controls. Convalescent COVID-19 patients with lingering symptoms (“long haulers”) showed persistent up-regulation of caspase-1 in CD4 T cells that was attenuated ex vivo following co-culture with a select pan-caspase inhibitor. Further, we observed elevated caspase-3 levels in red blood cells from COVID-19 patients compared to controls that were responsive to caspase inhibition. Our results expose an exuberant caspase response in COVID-19 that may facilitate immune-related pathological processes leading to severe outcomes. Pan-caspase inhibition could emerge as a therapeutic strategy to ameliorate or prevent severe COVID-19 outcomes.Competing Interest StatementNone of the authors have any relevant conflict of interest to disclose with the exception of L.C.N. has received fees from Abbvie within the past year and has received compensation for serving on a scientific advisory board for Cytodyn for work unrelated to this project. All other authors declare no competing interests.Funding StatementNone for the study. L.C.N. is supported by several NIH awards including from the National Institute of Mental Health (R01 MH112457) and National Institute of Allergy and Infectious Diseases (UM1 AI126617) BELIEVE Collaboratories.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Western IRB: 1285028 for Amerimmune S.U.N.Y. Downstate IRB 269846-10 for SUNY Downstate Medical CenterAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data regarding the manuscript is available on request